Skip to main content

Table 2 Probabilistic Sensitivity Analysis results. QALY: Quality-Adjusted Life Years, ICER: Incremental Cost-Effectiveness Ratio

From: Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry

  Step-up Initial Combination
Mean costs (€) €20,163.81 €16,267.15
2.5–97.5% interval 16,588.46–23,780.33 11,534.72–21,366.87
Mean utility (QALY) 3.515 3.548
2.5–97.5% interval 2.467–4.598 2.44–4.71
ICER −119,897 (Dominating)